Back to top

Image: Bigstock

Is Abeona Therapeutics (ABEO) Stock a Solid Choice Right Now?

Read MoreHide Full Article

One stock that might be an intriguing choice for investors right now is Abeona Therapeutics, Inc. . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 63 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

ABEONA THERAPTC Price and Consensus

In fact, over the past month, current quarter estimates have narrowed from a loss of 15 cents per share to a loss of 12 cents, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 66 cents per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Abeona Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Abeona Therapeutics Inc. (ABEO) - free report >>

Published in